Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this extension study was to assess the long term safety of patients
with nonfunctioning enteropancreatic neuroendocrine tumour (NET), who were treated with open
label lanreotide Autogel (120 mg every 28 days) and who participated in a previous study,
2-55-52030-726 (NCT00353496).